Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.94 USD | +6.41% | +37.06% | +75.16% |
04-17 | North American Morning Briefing : Stock Futures -2- | DJ |
04-16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
Business Summary
Number of employees: 19
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
73.2
%
| 3 | 18.6 % | 1 | 73.2 % | -58.15% |
License and Other
26.8
%
| 15 | 81.4 % | 1 | 26.8 % | -96.49% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -89.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 31/01/20 |
Director of Finance/CFO | 40 | 31/12/17 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Lisa Hegg
CTO | Chief Tech/Sci/R&D Officer | - | - |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 09/11/21 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 11/10/20 |
Garry Neil
CEO | Chief Executive Officer | 70 | 31/01/20 |
Director/Board Member | 64 | 27/08/12 | |
Mitchell Chan
BRD | Director/Board Member | 43 | 30/11/21 |
Company contact information
Avalo Therapeutics, Inc.
540 Gaither Road Suite 400
20850, Rockville
+410 522 8707
http://www.avalotx.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.16% | 16.48M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AVTX Stock
- Company Avalo Therapeutics, Inc.